CONTEXTVISION AB |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6 NOK | -1.64% |
|
-4.76% | -22.08% |
| Apr. 03 | ContextVision Announces New Image Quality Advancements in X-Ray | CI |
| Feb. 16 | Transcript : ContextVision AB, Q4 2023 Earnings Call, Feb 16, 2024 |
| Sales 2024 * | 136M 12.41M | Sales 2025 * | 142M 12.97M | Capitalization | 472M 42.96M |
|---|---|---|---|---|---|
| Net income 2024 * | 23M 2.09M | Net income 2025 * | 24M 2.18M | EV / Sales 2024 * | 3.08 x |
| Net cash position 2024 * | 51.78M 4.71M | Net cash position 2025 * | 46.39M 4.22M | EV / Sales 2025 * | 2.99 x |
| P/E ratio 2024 * |
20
x | P/E ratio 2025 * |
19.4
x | Employees | 40 |
| Yield 2024 * |
6.67% | Yield 2025 * |
7.51% | Free-Float | 34.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on ContextVision AB
More press releases
| 1 day | -1.64% | ||
| 1 week | -4.76% | ||
| Current month | -11.76% | ||
| 1 month | -10.98% | ||
| 3 months | -28.91% | ||
| 6 months | -20.42% | ||
| Current year | -22.08% |
1 week
5.90
6.38
1 month
5.906.98
Current year
5.909.20
1 year
5.909.88
3 years
5.9027.10
5 years
5.0530.90
10 years
1.4430.90
| Managers | Title | Age | Since |
|---|---|---|---|
Gerald Pötzsch
CEO | Chief Executive Officer | 52 | 22-07-31 |
| Director of Finance/CFO | - | 23-08-27 | |
Gunnar Läthén
CTO | Chief Tech/Sci/R&D Officer | - | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Martin Hedlund
FOU | Founder | 72 | 82-12-31 |
Lars Olof Sandèn
CHM | Chairman | 62 | 21-05-04 |
| Founder | 70 | 82-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 6 | -1.64% | 86 374 |
| 24-04-25 | 6.1 | 0.00% | 2,211 |
| 24-04-24 | 6.1 | 0.00% | 9,670 |
| 24-04-23 | 6.1 | -0.65% | 58,849 |
| 24-04-22 | 6.14 | -2.54% | 84,618 |
Real-time Oslo Bors, April 26, 2024 at 06:22 am EDT
More quotes
ContextVision AB is a Sweden-based medical technology software company specialized in image analysis and artificial intelligence. The Company is engaged in the image enhancement market and is a partner to the manufacturers of ultrasound, X-ray and Magnetic Resonance Imaging (MRI) equipment around the world. The Company develops software products, based on proprietary technology and artificial intelligence for image-based applications. ContextVisionâs cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The Company operates through two separate segments: the Business Unit Medical Imaging and the Business Unit Digital Pathology. ContextVision has two subsidiaries: Inify Laboratories AB og ContextVision Inc.
Calendar
2024-05-08
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
6.1
NOK
Average target price
7.5
NOK
Spread / Average Target
+22.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.08% | 42.95M | |
| +3.41% | 32.18B | |
| +14.14% | 7.33B | |
| +23.27% | 3.83B | |
| -14.26% | 3.23B | |
| -27.90% | 1.25B | |
| -34.43% | 1.12B | |
| +2.01% | 912M | |
| -24.21% | 856M | |
| -38.47% | 859M |
- Stock Market
- Equities
- CONTX Stock
